MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Sage Therapeutics, Inc. (NASDAQ: SAGE)*
Organization & Developments: Sage
Parents
Sage Therapeutics, Inc. (NASDAQ: SAGE)*
Children
*Has a drug in development for prolonged seizures called status epilepticus as well as other diseases of the central nervous system
2014: Sage reports early success in trial of drug to treat severe epilepsy
2016: Some Sage Advice On This Small-Cap Biotech Concern - Sage Therapeutics (NASDAQ:SAGE)
2017: What's Next For Sage Therapeutics? - Sage Therapeutics (NASDAQ:SAGE)
2019: An Update On Sage Therapeutics_seekingalpha.com
2019: Sage Therapeutics Continues To Push Forward With Multiple Positive CNS Studies - Sage Therapeutics (NASDAQ:SAGE)
2019: Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation_seekingalpha.com
2019: Sage_FDA approves trailblazing postpartum depression therapy, in crucial milestone for women’s health – Endpoints News
2020: Sage Therapeutics Dives On $1.5 Billion Collaboration Deal With Biogen
2021: Sage Therapeutics: Steady Recovery After Biogen Deal
2022: Sage Therapeutics Could Be In For A Depressing FDA Review_ seekingalpha.com
2022: Sage Therapeutics: Zuranolone NDA Near-Term Tailwind_ seekingalpha.com
2023: Postpartum Pioneer Or Fiscal Folly, Zurzuvae Dilemma (NASDAQ:SAGE)
2023: Sage braces for layoffs, pipeline cuts as shares tank in wake of zuranolone's MDD rejection
2023: Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone_fiercebiotech
2023: Sage Therapeutics: Postpartum Pioneer Or Fiscal Folly, Zurzuvae Dilemma
2023: Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024
2024: CNS Drug Development: Same As It Ever Was
2024: In downsizing mode, Sage will move headquarters to a smaller space
2024: Sage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade
2024: Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
2024: Sage to cut one-third of workforce, streamline drug pipeline
2024: Sizing Up Sage Therapeutics_ seekingalpha.com
2025: Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
2025: Sage Therapeutics: Looks Like A 'Strong Buy' With Zurzuvae_ seekingalpha.com
Jumps
*Key People: Sage
Finance & Acquisitions: Sage